D1.124 - Changes in respiratory infections patterns in Patients with Severe Asthma and a High burden of comorbidities treated with tezepelumab: interim analysis results of the T-ROSS II study

Patients with Severe Asthma (SA) have a high burden of comorbidities that can significantly impact their health, including an increased susceptibility to respiratory infections.

The T-ROSS II is an ongoing, retrospective, multicenter study conducted in severe asthma patients treated with tezepelumab in Spain. This interim analysis assessed the main comorbidities and respiratory infections in the 12-month baseline period prior to starting tezepelumab treatment and in 12 months follow-up period.

Of the 198 patients included in this analysis, 136 (68.7 %) were female, and the mean (SD) age was 55.9 (14.7) years. The most common respiratory comorbidities included allergic rhinitis (35.8%), obstructive sleep apnea (19.7%), chronic rhinosinusitis with nasal polyps (CRSwNP) (8.1%) and bronchiectasis (9.6%). The most common general comorbidities were obesity (27.8%), hypertension (24.3%), anxiety (21.7%), gastroesophageal reflux disease (20.7%) and depression (19.7%).

At baseline, 152 patients (79.17%) suffered respiratory infections. These respiratory infections numerically decrease from a mean (SD) of 1.9 (1.7) in the baseline to 0.9 (1.1) during follow-up. The proportion of infection-free patients doubled during follow-up, increasing from 20.8% to 44.9%.

The mean (SD) number of respiratory infections treated with antibiotics were 1.3 (1.4) in the baseline and 0.6 (1.0) during follow-up. The proportion of patients that received flu vaccination was similar during baseline and follow-up (67.2% vs 61.8%).

In the current era of biologics, the cohort of the T-ROSS II study, showed a marked reduction in respiratory infections after the start of tezepelumab treatment in patients with SA and a high burden of comorbidities.